Inhibition of SLC25A1 or ACLY leads to impaired cancer cell proliferation, differentiation, and sensitization to immune therapy, highlighting their role as potential effective targets for anti-cancer strategy (Huang et al, 2022; Wartewig et al, 2023; Xiang et al, 2023; Zhang et al, 2023). The gene discussed is SLC25A1; the disease is cancer.